Evaluation of inflammatory and coagulation markers in patients with idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension with comorbid hypercholesterolemia

The aim of the study was to assess inflammatory and coagulation disorders in patients with idiopathic pulmonary arterial hypertension (IPAH) and chronic thromboembolic pulmonary hypertension (CTEPH) in dependence on dyslipidemia. Methods. The study involved 22 patients with IPAH and 6 patients with inoperable CTEPH complicated by hypercholesterolemia (total cholesterol (TC) level > 5.8 mmol/L). Healthy volunteers with normal TC level (n = 20) were included in a control group. We measured serum cytokine concentrations, such as interleukin (IL)-2, IL-4, IL-5, IL-6, IL-10, IL-12, and interferon (INF)-γ, using a multiplex fluorescent analyzer GEN-PROBE (Luminex 200) with Bio-Plex Precision Pro set. Von Willebrand factor was measured using an immunoturbidimetric assay with STA-Liatest VWF: Ag set. D-dimer, fibrinogen, C-reactive protein, and the total blood cell count were also measured. Results. CTERH patients had lower IL-2 level and more prominent signs of chronic heart failure (CHF) compared to patients with IPAH. Serum levels of IL-10, IL-4, and IL-12 were significantly related to syncope frequency, INF-γ level and cardiac index (CI). High density lipoprotein (HDL) level was inversely related to mean pulmonary arterial pressure (mPAP) in IPAH/CTEPH patients with TC > 6.5 mmol/L. Decreased thrombocyte count and decreased thrombocrit were associated with increased mPAP and mean right atrium (RA) pressure in patients with dilated right pulmonary artery. Increased D-dimer level was associated with enlarged RA area, enlarged right ventricle size, tricuspid regurgitation and decreased CI. Conclusion. Serum concentrations of the inflammatory and coagulation markers, excepting LI-2, did no differ significantly in patients with IPAH and CTEPH. Dyslipidemia was associated with activation of inflammation. Further studies are needed to estimate a predictive value of decreased HDL in patients with IPAH and CTEPH.

idiopathic pulmonary arterial hypertension, chronic thromboembolic pulmonary hypertension, inflammation, coagulation hemostasis, hypercholesterolemia

1. Yuan J.X., Rubin L.J. Pathogenesis of pulmonary arterial hypertension: the need for multiple hits. Circulation. 2005; 111 (5): 534–538. DOI: 10.1161/01.CIR.0000156326.48823.55.

2. Dorfmuller P., Perros F., Balabanian K., Humbert M. Inflammation in pulmonary arterial hypertension. Eur. Respir. J. 2003; 22 (2): 358–363. DOI: 10.1183/09031936.03.00038903.

3. Blum L.K., Cao R.R.L., Sweatt A.J. et al. Circulating plasmablasts are elevated and produce pathogenic anti-endothelial cell autoantibodies in idiopathic pulmonary arterial hypertension. Eur. J. Immunol. 2018; 48 (5): 874–884. DOI: 10.1002/eji.201747460.

4. Martynjuk T.V., Zykov K.A., Antonova O.Ju. et al. [Effect of bosentan on clinical status and cellular immunity of patients with idiopathic pulmonary hypertension]. Terapevticheskij arhiv. 2013; 85 (1): 25–31 (in Russian).

5. Tuder R.M., Groves B., Badesch D.B., Voelkel N.F. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am. J. Pathol. 1994; 144 (2): 275–285.

6. Frid M.G., Brunetti J.A., Burke D.L. et al. Hypoxia-induced pulmonary vascular remodeling requires recruitment of circulating mesenchymal precursors of a monocyte/macrophage lineage. Am. J. Pathol. 2006; 168 (2): 659–669. DOI: 10.2353/ajpath.2006.050599.

7. Perros F., Dorfmuller P., Souza R. et al. Fractalkine-induced smooth muscle cell proliferation in pulmonary hypertension. Eur. Respir. J. 2007; 29 (5): 937–943. DOI: 10.1183/09031936.00104706.

8. Stenmark K.R., Davie N.J., Reeves J.T., Frid M.G. Hypoxia, leukocytes, and the pulmonary circulation. J. Appl. Physiol. 2005; 98 (2): 715–721. DOI: 10.1152/japplphysiol.00840.2004.

9. Tuder R.M., Marecki J.C., Richter A. et al. Pathology of pulmonary hypertension. Clin. Chest Med. 2007; 28 (1): 23–42. DOI: 10.1016/j.ccm.2006.11.010.

10. Nakonechnikov C.N., Zykov K.A., Martynjuk T.V. et al. [A pattern of proinflammatory markers in patients with different types of pulmonary hypertension]. Sistemnye gipertenzii. 2010; (3): 61–66 (in Russian).

11. Nakonechnikov S.N., Zykov K.A., Rvacheva A.V. et al. The features of inflammatory pattern at different forms of pulmonary hypertension. Kubanskiy nauchnyy meditsinskiy vestnik. 2010; 8 (122): 141–147 (in Russian).

12. Rubin L.J. Therapy of pulmonary hypertension: the evolution from vasodilators to antiproliferative agents. Am. J. Respir. Crit. Care Med. 2002; 166 (10): 1308–1309. DOI: 10.1164/rccm.2208008.

13. Chazova I.E., Martynjuk T.V., Nakonechnikov S.N. [Results of European Congress of Cardiology 2015: a new version of guidelines for diagnosis and treatment of pulmonary hypertension]. Evraziĭskiĭ kardiologicheskiĭ zhurnal. 2015; (4): 3–10 (in Russian).

14. Kawut S.M., Horn E.M., Berekashvili K.K. et al. von Willebrand factor independently predicts long-term survival in patients with pulmonary arterial hypertension. Chest. 2005; 128 (4): 2355–2362. DOI: 10.1378/chest.128.4.2355.

15. Can M.M., Tanboğa I.H., Demircan H.C. et al. Enhanced hemostatic indices in patients with pulmonary arterial hypertension: An observational study. Thromb. Res. 2010; 126 (4): 280–282. DOI: 10.1016/j.thromres.2010.06.020.

16. Galie` N., Humbert M., Vachiery J.L. et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur. Respir. J. 2015; 46 (4): 903–975. DOI: 10.1183/13993003.01032-2015.

17. Kawut S.M., Bagiella E., Lederer D.J. et al. Randomized clinical trial of aspirin and simvastatin for pulmonary arterial hypertension: ASA-STAT. Circulation. 2011; 123 (25): 2985–2993. DOI: 10.1161/CIRCULATIONAHA.110.015693.

18. Chen C.C., Manning A.M. TGF-β1, IL-10 and IL-4 differentially modulate the cytokine-induced expression of IL-6 and IL-8 in human endothelial cells. Cytokine. 1996; 8 (1): 58–65. DOI: 10.1006/cyto.1995.0008.

19. Soon E., Holmes A.M., Treacy C.M. et al. Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. Circulation. 2010; 122 (9): 920–927. DOI: 10.1161/CIRCULATIONAHA.109.933762.

20. Zhao Q.H., Peng F.H., Wei H. et al. Serum high-density lipoprotein cholesterol levels as a prognostic indicator in patients with idiopathic pulmonary arterial hypertension. Am. J. Cardiol. 2012; 110 (3): 433–439. DOI: 10.1016/j.amjcard.2012.03.042.

21. Heresi G.A., Aytekin M., Newman J. et al. Plasma levels of high-density lipoprotein cholesterol and outcomes in pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 2010; 182 (5): 661–668. DOI: 10.1164/rccm.201001-0007OC.

22. Larsen C.M., McCully R.B., Murphy J.G. et al. Usefulness of high-density lipoprotein cholesterol to predict survival in pulmonary arterial hypertension. Am. J. Cardiol. 2016; 118 (2): 292–297. DOI: 10.1016/j.amjcard.2016.04.028.

23. Taraseviciene-Stewart L., Scerbavicius R., Choe K.H. et al. Simvastatin causes endothelial cell apoptosis and attenuates severe pulmonary hypertension. Am. J. Physiol. Lung Cell. Mol. Physiol. 2006; 291 (4): 668–676. DOI: 10.1152/ajplung.00491.2005.

24. Chen L., Nakano K., Kimura S. et al. Nanoparticle-mediated delivery of pitavastatin into lungs ameliorates the development and induces regression of monocrotaline-induced pulmonary artery hypertension. Hypertension. 2011; 57 (2): 343–350. DOI: 10.1161/HYPERTENSIONAHA.110.157032.

25. Rysz-Górzynska M., Gluba-Brzózka A., Sahebkar A. et al. Efficacy of statin therapy in pulmonary arterial hypertension: A systematic review and meta-analysis. Sci. Rep. 2016; 6: 30060. DOI: 10.1038/srep30060.

26. Holzhauser L., Hovnanians N., Eshtehardi P. et al. Statin therapy improves survival in patients with severe pulmonary hypertension: a propensity score matching study. Heart Vessels. 2017; 32 (8): 969–976. DOI: 10.1007/s00380-017-0957-8.